Advert - Boehringer Ingelheim and Lilly

For distributing a letter regarding Jardiance (empagliflozin) that prepared the market for an anticipated licence extension, Boehringer Ingelheim and Lilly were ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.

Clause 3.2 - Using material that was inconsistent with the summary of product characteristics and promoted an unlicensed indication.

Clause 9.1 - Failing to maintain high standards.

Clause 12.1 - Disguising promotional materials.

The Code of Practice Panel reported Boehringer Ingelheim and Lilly to the Code of Practice Appeal Board which subsequently required
both companies to issue a corrective statement to recipients of the item at issue.

The interim case report which includes the wording of the corrective statement is available at www.pmcpa.org.uk.

Advert - November 2016